MedTrace Logo

Comparison of Serratus Posterior Superior Intercostal Plane Block and Deep Serratus Anterior Plane Block After Video-Assisted Thoracoscopic Surgery

NCT07553195 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-11

No results posted yet for this study

Summary

This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Serratus Posterior Superior Intercostal Plane (SPSIP) and Deep Serratus Anterior Plane Block in patients undergoing Video-Assisted Thoracoscopic Surgery. The primary outcome is Visual Analog Scale (VAS) during the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection), Patient satisfaction assessed using a Likert scale, Quality of recovery assessed using the QoR-15 questionnaire.

Conditions

  • Postoperative Pain
  • Video Assisted Thoracic Surgery (VATS)
  • Serratus Posterior Superior Intercostal Plane Block
  • Deep Serratus Anterior Plane Block

Interventions

PROCEDURE

Serratus Posterior Superior Intercostal Plane (SPSIP) block

Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.

PROCEDURE

Deep Serratus Anterior Plane Block (Deep SAP)

Patients in this group will receive an ultrasound-guided Deep Serratus Anterior Plane Block (Deep SAP) with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus anterior muscle and the external intercostal muscles at the level of the 5th rib in the mid-axillary line.

Sponsors & Collaborators

  • Antalya City Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-30
Primary Completion
2027-12-30
Completion
2028-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07553195 on ClinicalTrials.gov